•   
    ASRS 2019
    05:09
    Retina/Vitreous

    In this interview from ASRS 2019, Dr. John Thompson reports on the incidence of silicone oil microdroplets following multiple injections of bevacizumab, ranibizumab or aflibercept. His analysis, which follows a 2017 study led by Dr. Rahul Khurana, included eyes that had received either of the 3 anti-VEGF agents and found oil droplets in 78% of bevacizumab-injected eyes, 48% of aflibercept eyes and 14% of ranibizumab eyes. Bevacizumab-associated oil bubbles tended to be more prominent. By contrast, he did not observe any silicone oil in a small group of eyes that were injected with prefilled, silicone-free ranibizumab syringes. He suggests that physicians should use silicone-free syringes for delivering bevacizumab.

    Relevant Financial Disclosures: Dr. Thompson is a consultant for and receives grant support from Genentech.